Delivery Order SPE2DB22D1106-SPE2DB25FFCS0
- Not listed
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $16,140.92. This firm fixed-price delivery order is non-set-aside and reflects open competition, with an ultimate completion date of August 8, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $8,586.45 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract represents a firm fixed price, non-competitive delivery order with performance scheduled for completion by July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a $11,468.93 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a completion date of August 12, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The vendor will perform this work from its corporate office in Conshohocken, Pennsylvania, where...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFCS0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $4,253.28. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026, which serves as a comprehensive pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor specializing in medical procurement for military and veteran healthcare systems. The company holds an extensive portfolio of federal contract awards with the Defense Logistics Agency covering a broad range of pharmaceutical products, vaccines, medical devices, and specialized healthcare commodities. This particular delivery order for Dupixent, a prescription biologic medication used in the treatment of certain allergic and inflammatory conditions, reflects the company's ongoing role in supplying specialized medical products to support Defense Health Agency and other federal healthcare systems. The contract contains no set-aside designation, indicating it was awarded through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/11/25 |